Haymarket Media, Inc.

Issue Archive | About Us | Contact Us | Subscribe | Editorial Board | Author Guidelines | About Haymarket Media

ONA

Subscribe to our RSS feeds

RSS | Login | Register

CLOSE

Register for your FREE account now and join thousands of oncology professionals who stay informed about patient care issues, practical oncology-care management techniques, and drug administration and dosage information.

Email*

Password*

Keep me logged in Forgot your password?

Email*

Register now »

Clinical Trial: Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma (ELOQUENT - 2)

November 18, 2011

Print
Email
Reprint
Text: A | A | A

More Multiple Myeloma Clinical Trials

More in Multiple Myeloma Clinical Trials:

Clinical Trial: Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma (ELOQUENT - 1)

Clinical Trial: Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma (ELOQUENT - 2)

Sponsor and Collaborators

Bristol-Myers Squibb

Abbott Biotherapeutics

ClinicalTrials.gov Identifier

NCT01239797

You must be a registered member of ONA to post a comment.

Click here to login | Click here to register

Web Exclusives

Posttransplant lenalidomide can slow down multiple myeloma

Delicia Honen Yard May 29, 2012

Lenalidomide use after autologous stem-cell transplant significantly improved progression-free and overall survival in patients with myeloma.

Melanoma genome study implicates sun and new genetic culprits

Delicia Honen Yard May 28, 2012

Genetic mutations increased along with chronic sun exposure in persons with melanoma, and yet another gene may contribute to disease risk as well.

Modified stem cells keep glioblastoma at bay

Delicia Honen Yard May 25, 2012

Three patients with glioblastoma lived longer than predicted after receiving transplants of their own blood stem cells that had been gene-modified.

Oncology Nurse Advisor Sitemap

Other Haymarket Medical Websites

MPR (drug database)

Clinical Advisor

JAAPA

myCME - Online CME

McKnights Long Term Care News

Renal and Urology News

Chemotherapy Advisor

International

GPonline

MIMS (drug database)

© 2012 Haymarket Media, Inc.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions